This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
The U.S. FDA-approved Telmisartan +Hydrocholrthiazide +Amlodipine for treating hypertension on November 16, 2009. Telmisartan+ Hydrocholrthiazide +Amlodipine belongs to the group of medications called antihypertensives.
Mechanism of Action of undefined
Telmisartan works by preventing the action of certain substances that tighten blood vessels. It improves blood flow and increases the heart's ability to pump blood effectively throughout the body. Amlodipine acts by relaxing and enlarging the blood vessels. The function of hydrochlorothiazide is to eliminate excess water and electrolytes from the body through urine. Hence, Telmisartan +Hydrocholrthiazide +Amlodipine lowers high blood pressure and lowers the risk of heart attacks and strokes.
Uses of undefined
Telmisartan +Hydrocholrthiazide +Amlodipine is primarily used for the treatment of hypertension. Hypertension (high blood pressure) is a medical condition in which blood exerts a force on the artery walls (blood vessels), resulting in heart disease, irregular heartbeat, and other problems.
undefined Drug administaration and Dosage available
Take the Telmisartan +Hydrocholrthiazide +Amlodipine as your physician advises. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.
Warnings, Precautions and Side Effects of undefined
Telmisartan +Hydrocholrthiazide +Amlodipine should not be consumed if you are allergic to Telmisartan +Hydrocholrthiazide +Amlodipine or any of its ingredients in the medication. Report to your doctor immediately if you have anuria (kidney failure that causes less urine production) and diabetes. It is not recommended for people with hypotension (low blood pressure), liver and kidney disease, heart failure, electrolytes, and metabolic disorders. This medication is not intended to be used during the second and third trimesters of pregnancy, as it reduces fetal renal function and causes harmful effects on the developing fetus.
Notify your doctor if you are pregnant, planning to get pregnant, or think you may be pregnant or breastfeeding. Calcium citrate+Vitamin D3+Zinc +Magnesium should be used cautiously in liver patients. Before starting the treatment, inform your physician about pre-existing liver conditions. Avoid consuming alcohol while taking Telmisartan +Hydrocholrthiazide +Amlodipine, as it may cause unpleasant side effects. Do not drive or operate machinery because Telmisartan +Hydrocholrthiazide +Amlodipine can cause dizziness, drowsiness, or tiredness.
The most common side effects of Telmisartan +Hydrocholrthiazide +Amlodipine are sleepiness, ankle swelling, nausea, headache, flushing, dizziness, fatigue (tiredness), palpitations, stomach upset, peripheral edema, and mood changes.
Word Of Advice
Do not breastfeed while taking Pregabalin unless your doctor advises. Notify your doctor if you experience any serious side effects. Your medical professional will inform you if you need any dose adjustments. Contact your doctor for more information.
It is advised to restrict salt intake in the diet. If you have a history of heart failure and hypotension, monitoring your blood pressure regularly is suggested. Drink plenty of water and fluids to keep yourself hydrated.
Frequently Asked Question
- KD Tripathi, Essentials of Medical Pharmacology, Antihypertensive drugs, 7th edition. 2013, 561-563.
- Sanofi India Limited, [Accessed on 13th June 2023]; https://www.sanofi.in/dam/jcr:f1d59d7f-bfe7-456b-9f95-02f66fb22cb7/Telsite%20AM%20H%20PI%20June%202018.pdf
- Accord Healthcare Limited; Electronic Medicines Compendium (EMC), [Revised on January 2022] [Accessed on 13th June 2023], https://www.medicines.org.uk/emc/product/6126/smpc#gref
- Pfizer labs; US Food and Drug Administration, [ Revised on May 2011] [ Accessed on 13th June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf
- Bonchringer Ingelheim Phramaceuticals Inc., US Food and Drug Administration, [ Revised on Oct 2009] [ Accessed on 13th June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022401lbl.pdf
The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.